Your browser is no longer supported. Please, upgrade your browser.
ABBV AbbVie Inc. monthly Stock Chart
ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E22.93 EPS (ttm)4.57 Insider Own0.10% Shs Outstand1.77B Perf Week5.24%
Market Cap183.96B Forward P/E8.61 EPS next Y12.19 Insider Trans-23.46% Shs Float1.76B Perf Month30.31%
Income7.32B PEG2.47 EPS next Q2.86 Inst Own70.20% Short Float0.79% Perf Quarter11.38%
Sales40.65B P/S4.53 EPS this Y42.30% Inst Trans-0.96% Short Ratio1.68 Perf Half Y15.64%
Book/sh8.63 P/B12.15 EPS next Y16.33% ROA6.10% Target Price111.33 Perf Year18.75%
Cash/sh4.53 P/C23.14 EPS next 5Y9.27% ROE203.50% 52W Range62.55 - 104.82 Perf YTD18.47%
Dividend5.20 P/FCF22.66 EPS past 5Y36.80% ROI21.20% 52W High0.07% Beta0.81
Dividend %4.96% Quick Ratio0.80 Sales past 5Y10.80% Gross Margin68.60% 52W Low67.69% ATR2.37
Employees47000 Current Ratio1.00 Sales Q/Q52.20% Oper. Margin28.50% RSI (14)76.99 Volatility1.92% 2.40%
OptionableYes Debt/Eq5.70 EPS Q/Q2.20% Profit Margin18.00% Rel Volume0.53 Prev Close104.20
ShortableYes LT Debt/Eq5.39 EarningsOct 30 BMO Payout100.60% Avg Volume8.34M Price104.89
Recom2.00 SMA209.32% SMA5016.35% SMA20016.97% Volume4,418,751 Change0.66%
Nov-10-20Resumed Bernstein Outperform $120
Sep-29-20Initiated Berenberg Hold $98
Jun-23-20Upgrade Atlantic Equities Neutral → Overweight $115
Jun-09-20Upgrade Wolfe Research Peer Perform → Outperform
Jun-02-20Upgrade Argus Hold → Buy $115
May-18-20Resumed BofA/Merrill Neutral $95
May-12-20Upgrade JP Morgan Neutral → Overweight $105
May-11-20Resumed Morgan Stanley Overweight $95
Apr-20-20Upgrade RBC Capital Mkts Sector Perform → Outperform $79 → $93
Mar-23-20Downgrade Societe Generale Buy → Hold
Feb-27-20Initiated Barclays Equal Weight $97
Feb-06-20Initiated Mizuho Buy
Jan-07-20Initiated RBC Capital Mkts Sector Perform $86
Dec-26-19Reiterated Cowen Outperform $90 → $98
Sep-26-19Upgrade Citigroup Neutral → Buy $87 → $90
Aug-20-19Upgrade Piper Jaffray Neutral → Overweight $80
Jun-27-19Upgrade Wolfe Research Underperform → Peer Perform
Jun-26-19Upgrade SVB Leerink Mkt Perform → Outperform $88
May-28-19Initiated Goldman Neutral
Apr-29-19Upgrade BMO Capital Markets Underperform → Market Perform
Nov-29-20 11:30AM  
Nov-28-20 06:24AM  
Nov-27-20 10:58AM  
08:52AM  
Nov-25-20 01:48PM  
01:01PM  
07:22AM  
Nov-24-20 10:14AM  
09:06AM  
08:00AM  
Nov-23-20 10:00PM  
10:50AM  
07:56AM  
Nov-22-20 06:08AM  
Nov-21-20 07:30AM  
06:12AM  
Nov-20-20 08:01AM  
Nov-19-20 04:36PM  
Nov-18-20 05:00PM  
06:08AM  
01:29AM  
Nov-17-20 10:31AM  
10:09AM  
06:43AM  
Nov-16-20 07:56PM  
06:54PM  
06:39PM  
05:57PM  
05:49PM  
05:30PM  
04:30PM  
01:54PM  
10:38AM  
10:28AM  
09:30AM  
08:00AM  
07:00AM  
Nov-13-20 07:18PM  
04:05PM  
Nov-12-20 08:00AM  
Nov-10-20 12:35PM  
08:00AM  
Nov-09-20 04:58PM  
Nov-07-20 12:31AM  
Nov-06-20 10:00AM  
07:00AM  
Nov-05-20 09:00AM  
08:50AM  
Nov-04-20 04:39PM  
Nov-03-20 05:57PM  
10:48AM  
Nov-02-20 11:45AM  
10:21AM  
08:36AM  
07:48AM  
07:00AM  
06:03AM  
05:55AM  
Nov-01-20 03:30PM  
07:09AM  
Oct-31-20 06:40AM  
06:01AM  
Oct-30-20 04:30PM  
02:18PM  
12:15PM  
11:45AM  
09:42AM  
09:05AM  
08:13AM  
08:05AM  
07:53AM  
07:47AM  
07:47AM  
07:15AM  
07:00AM  
Oct-29-20 10:04AM  
07:30AM  
02:05AM  
Oct-28-20 06:51PM  
04:48PM  
12:08PM  
08:31AM  
08:00AM  
Oct-27-20 06:12AM  
Oct-26-20 05:45PM  
07:11AM  
Oct-23-20 12:30PM  
10:48AM  
10:05AM  
Oct-22-20 10:15AM  
Oct-21-20 11:45AM  
Oct-20-20 05:45PM  
11:52AM  
03:46AM  
Oct-19-20 06:55PM  
10:06AM  
09:27AM  
08:56AM  
Oct-17-20 06:50AM  
Oct-16-20 07:34PM  
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Jacobio Pharmaceuticals; I-Mab; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gosebruch Henry OEVP, Chief Strategy OfficerNov 20Sale99.3840,0003,975,04620,006Nov 24 05:34 PM
ALBAN CARLOSVice ChairmanNov 16Option Exercise35.88115,8304,155,980230,729Nov 18 05:04 PM
ALBAN CARLOSVice ChairmanNov 16Sale100.00115,83011,583,000114,899Nov 18 05:04 PM
GONZALEZ RICHARD AChairman of the Board and CEONov 12Option Exercise57.12194,15411,089,858512,796Nov 12 05:54 PM
GONZALEZ RICHARD AChairman of the Board and CEONov 12Sale97.10194,15418,851,790318,642Nov 12 05:54 PM
SALEKI-GERHARDT AZITAEVP, OperationsNov 10Sale98.0017,4261,707,74896,441Nov 12 05:56 PM
GONZALEZ RICHARD AChairman of the Board and CEONov 09Sale95.7437,4503,585,463318,642Nov 12 05:54 PM
SALEKI-GERHARDT AZITAEVP, OperationsNov 04Sale93.614,800449,328109,067Nov 06 04:29 PM
SEVERINO MICHAELVice ChairmanNov 04Sale93.6190,6798,488,46167,281Nov 06 04:29 PM
ALBAN CARLOSVice ChairmanJul 07Sale100.0053,3255,332,555114,899Jul 08 09:19 PM
Stewart Jeffrey RyanSVP, US Commercial OperationsMay 12Sale90.0023,0242,072,21152,760May 12 05:44 PM
RICHMOND TIMOTHY J.EVP, Chief HR OfficerMay 05Sale85.0019,4451,652,8250May 07 05:01 PM
Durkin Brian LVP, ControllerMar 30Buy69.0075051,75016,844Mar 20 04:56 PM
Durkin Brian LVP, ControllerMar 20Buy67.5080054,00016,094Mar 20 04:56 PM
Durkin Brian LVP, ControllerMar 18Buy68.182,200150,00515,294Mar 20 04:56 PM
RAPP EDWARD JDirectorMar 03Buy87.872,875252,6172,875Mar 04 05:14 PM